

CLINICAL PHARMACOLOGY & THERAPEUTICS

EDITOR

C. Michael Stein, MD

EDITOR EMERITUS

Marcus M. Reidenberg, MD

FOUNDING EDITOR

Walter Modell, MD (Deceased)

ASSOCIATE EDITORS

Arthur J. Atkinson, Jr, MD

Richard B. Kim, MD

David W. Nierenberg, MD

Grant R. Wilkinson, PhD

EDITORIAL BOARD

Darrell R. Abernethy, MD, PhD

Adedayo Adedoyin, PhD

Matthew M. Ames, PhD

Fred Y. Aoki, MD

Glen Apseloff, MD

Larry A. Bauer, PharmD

Leif Bertilsson, PhD

Terrence F. Blaschke, MD

R. A. Branch, MD

Eric P. Brass, MD, PhD

D. Craig Brater, MD

Alastair Breckenridge, MSc, MD

Douwe D. Breimer, PhD

Michael E. Brier, PhD

James F. Burris, MD

S. George Carruthers, MD, FRCPC

Dennis J. Chapron, RPh, MS

David M. Cocchetto, PhD

C. Lindsay DeVane, PharmD

Colin Dollery, MB, ChB, BSc

Margaret S. Dordal, MD, PhD

Akio Ebihara, MD

David J. Edwards, PharmD

Merrill J. Egorin, MD

Thomas Eissenberg, PhD

William E. Evans, PharmD

Ross D. Feldman, MD

Charles Flexner, MD

Marilynn C. Frederiksen, MD

Kathleen Giacomini, PhD

Jean Gray, MD, FRCP(C)

Linda E. Gustavson, PhD

Perry V. Halushka, MD, PhD

Thomas K. Henthorn, MD

Linda A. Hershey, MD, PhD

Peter H. Hinderling, MD

Takashi Ishizaki, MD

Patrice Jaillon, MD

William J. Jusko, PhD

Shigeru Kageyama, MD, PhD

Helen Kastrissios, PhD

Joan M. Korth-Bradley, PharmD, PhD

Juan J. L. Lertora, MD, PhD

Lionel D. Lewis, MB, BCh, MD

David T. Lowenthal, MD, PhD

Carl V. Manion, MD

Edward B. Nelson, MD

Michael C. Orme, MB, BS

Russell K. Portenoy, MD

William Z. Potter, MD, PhD

Mark J. Ratain, MD

Mary V. Relling, PharmD

Janice B. Schwartz, MD

Edward M. Sellers, MD, PhD, FRCP(C)

Steven L. Shafer, MD

Lewis B. Sheiner, MD

Alexander M. M. Shepherd, MD, PhD

Sang-Goo Shin, MD, PhD

Daniel S. Sitar, PhD

Folke Sjöqvist, MD, PhD

Donald R. Stanski, MD

Arnold B. Sterman, MD

John T. Sullivan, MB, ChB, FRACP

Robert Temple, MD

Andre Terzic, MD, PhD

Timothy S. Tracy, PhD

Elliot S. Vesell, MD

Robert E. Vestal, MD

John B. Warren, MD, FRCP

William B. White, MD

John T. Wilson, MD

Alastair J. J. Wood, MB, ChB

Raymond L. Woosley, MD, PhD

VOLUME 73, JANUARY-JUNE 2003
MOSBY, INC, ST LOUIS

CLINICAL PHARMACOLOGY & THERAPEUTICS

Official Publication of the
American Society for Clinical Pharmacology and Therapeutics
American Society for Pharmacology and Experimental Therapeutics

EDITORIAL COMMITTEE FOR THE JOURNAL

D. Craig Brater, MD, Indianapolis, Ind (ASCPT)
Alastair J. J. Wood, MD, Nashville, Tenn (ASCPT)
Scott A. Waldman, MD, PhD, Philadelphia, Pa (ASCPT)
Perry V. Halushka, MD, PhD, Charleston, SC (ASPET)
Darrell R. Abernethy, MD, PhD, Baltimore, Md (ASPET)
Gregory L. Kearns, PharmD, Kansas City, Mo (ASCPT)
Barbara A. Levey, MD, FACP, Los Angeles, Calif (ASCPT)
John J. Schrogie, MD, King of Prussia, Pa (ASCPT)

OFFICERS OF THE AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS

President: Gregory L. Kearns, PharmD, PhD, Kansas City, Mo
President-Elect: Andre Terzic, MD, PhD, Rochester, Minn
Secretary-Treasurer: John J. Schrogie, MD, King of Prussia, Pa
Chair, Editorial Committee: D. Craig Brater, MD, Indianapolis, Ind
Executive Director: Sharon J. Swan, CAE, Alexandria, Va

MEMBERS OF THE COUNCIL OF THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

President: Paul F. Hollenberg, PhD, Ann Arbor, Mich
President-Elect: David B. Bylund, PhD, Omaha, Neb
Secretary-Treasurer: James E. Barrett, PhD, Montvale, NJ
Chair, Board of Publications Trustees: Brian M. Cox, PhD, Bethesda, Md
Executive Officer: Christine K. Carrico, PhD, Bethesda, Md

Author index*

A

- Abdel-Rahman SM (see Lowry et al). 2003;73:209-22
 Abels R (see Noel et al). 2003;73:292-303
 Aberg JA (see Washington et al). 2003;73:406-16
 Adams J (see Klinkhardt et al). 2003;73:232-41
 Adedoyin A (see Carcillo et al). 2003;73:456-67
 AIDS Clinical Trials Group Protocol 378 (see Washington et al). 2003;73:406-16
 AIDS Clinical Trials Group 365 Study Team (see Hamzeh et al). 2003;73:159-69
 Al-Dam A (see Tegeder et al). 2003;73:417-26
 Andersson K (see Christensen et al). 2003;73:517-28
 Atkinson AJ Jr (see Rolan et al). 2003;73:284-91 (Commentary)
 Ayan-Oshodi M (see Skinner et al). 2003;73:170-7

B

- Backman JT (see Kyrklund et al). 2003;73:538-44
 Backman JT (see Lilja et al). 2003;73:192-8
 Badner J (see Sawyer et al). 2003;73:566-74
 Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. 2003;73:529-37
 Barst RJ, Ivy D, Dingemans J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PLM. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. 2003;73:372-82
 Bauersachs R (see Klinkhardt et al). 2003;73:232-41
 Baughman SA (see Wong et al). 2003;73:304-11
 Bebia Z (see Carcillo et al). 2003;73:456-67
 Becker M (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
 Bequembourg L (see Verstuyft et al). 2003;73:51-60
 Begg EJ (see Gardiner et al). 2003;73:71-7
 Bend JR (see Bailey et al). 2003;73:529-37
 Benson C (see Hamzeh et al). 2003;73:159-69
 Benson CT, Voelker JR. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. 2003;73:87-94
 Bertilsson L (see Christensen et al). 2003;73:517-28
 Bertino JS Jr (see Lowry et al). 2003;73:209-22
 Bertino JS Jr (see Rogers et al). 2003;73:153-8 (Commentary)
 Bingaman D (see Barst et al). 2003;73:372-82
 Biollaz J (see Csajka et al). 2003;73:20-30
 Blaschke TF (see Washington et al). 2003;73:406-16
 Bockbrader H (see Miller et al). 2003;73:491-505
 Boyett J (see Dervieux et al). 2003;73:506-16
 Boyett JM (see Sawyer et al). 2003;73:566-74
 Bradford LD (see Gaedigk et al). 2003;73:575-6 (Letter)
 Branch RA (see Carcillo et al). 2003;73:456-67
 Brass EP, Mayer MD, Mulford DJ, Stickler TK, Hoppel CL. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. 2003;73:338-47
 Bräutigam L (see Tegeder et al). 2003;73:417-26
 Briglia AE (see Dowling et al). 2003;73:427-34
 Brinkmann U (see Verstuyft et al). 2003;73:51-60
 Buclin T (see Csajka et al). 2003;73:20-30
 Burckart GJ (see Carcillo et al). 2003;73:456-67
 Burger P (see Miller et al). 2003;73:491-505
 Burhenne J (see Tayrouz et al). 2003;73:397-405

- Byrne DW (see Sofowora et al). 2003;73:366-71

C

- Calamia JC (see Park et al). 2003;73:543-53
 Cantarini MV (see Cooper et al). 2003;73:322-9
 Caraco Y (see Takahashi et al). 2003;73:253-63
 Carcillo JA, Adedoyin A, Burckart GJ, Frye RF, Venkataramanan R, Knoll C, Thummel K, Roskos L, Wilson JW, Sereika S, Romkes M, Bebia Z, Branch RA. Coordinated intrahepatic and extrahepatic regulation of cytochrome P4502D6 in healthy subjects and in patients after liver transplantation. 2003;73:456-67
 Cardus S (see Démolis et al). 2003;73:242-52
 Carithers RL Jr (see Park et al). 2003;73:543-53
 Chalon SA, Desager J-P, DeSante KA, Frye RF, Witcher J, Long AJ, Sauer J-M, Golnez J-L, Smith BP, Thomasson HR, Horsmans Y. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. 2003;73:178-91
 Chen X-P, Tan Z-R, Huang S-L, Huang Z, Ou-Yang D-S, Zhou H-H. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. 2003;73:264-71
 Cheng C (see Sawyer et al). 2003;73:566-74
 Chien S (see Noel et al). 2003;73:292-303
 Christensen M, Andersson K, Dalén P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar Ü, Bertilsson L. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. 2003;73:517-28
 Cnota H-P (see Hermann et al). 2003;73:61-70
 Comets E, Mentre F, Grass P, Kawai R, Marbach P, Vonderscher J. Population pharmacodynamic analysis of octreotide in acromegalic patients. 2003;73:95-106
 Cook E Jr (see Sawyer et al). 2003;73:566-74
 Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneek DW, Cantarini MV. Effect of itraconazole on the pharmacokinetics of rosuvastatin. 2003;73:322-9
 Corrigan B (see Miller et al). 2003;73:491-505
 Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. 2003;73:20-30
 Currier J (see Hamzeh et al). 2003;73:159-69

D

- Dalén P (see Christensen et al). 2003;73:517-28
 Dane AL (see Cooper et al). 2003;73:322-9
 Darimont J (see Skarke et al). 2003;73:107-21
 Das S (see Sawyer et al). 2003;73:566-74
 Décosterd LA (see Csajka et al). 2003;73:20-30
 de Hoog M, Mouton JW, van den Anker JN. Routine early therapeutic drug monitoring is necessary during the first week of life. 2003;73:131-2 (Letter reply)
 de Hoon JN, Pickkers P, Smits P, Struijker-Boudier HAJ, Van Bortel LMAB. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. 2003;73:312-21
 Démolis J-L, Vacheron F, Cardus S, Funck-Brentano C. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. 2003;73:242-52
 Dervieux T, Hancock ML, Pui C-H, Rivera GK, Sandlund JT, Ribeiro RC, Boyett J, Evans WE, Relling MV. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. 2003;73:506-16
 Desager J-P (see Chalon et al). 2003;73:178-91
 DeSante KA (see Chalon et al). 2003;73:178-91
 Deutsch P (see Hamzeh et al). 2003;73:159-69

*January, pp. 1-146; February, pp. P1-P126; March, pp. 147-274; April, pp. 275-386; May, pp. 387-480; June, pp. 481-590. Index to the ASCPT meeting abstracts is located in the February issue.

- Ding R (see Tayrouz et al). 2003;73:397-405
Dingemans J (see Barst et al). 2003;73:372-82
Dishy V (see Sofowora et al). 2003;73:366-71
Donahue JP, Dowdy D, Ratnam KK, Hulgán T, Price J, Unutmaz D, Nicotera J, Raffanti S, Becker M, Haas DW. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. 2003;73:78-86. Correction 2003;73:576
Doran A (see Barst et al). 2003;73:372-82
Dowdy D (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. 2003;73:427-34
Dreisbach AW, Japa S, Gebrekál AB, Mowry SE, Lertora JLL, Kamath BL, Rettie AE. Cytochrome P4502C₁₉ activity in end-stage renal disease. 2003;73:475-7 (Letter)
Drescher S, Glaeser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. 2003;73:223-31
Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. 2003;73:41-50
Dresser GK (see Bailey et al). 2003;73:529-37
Dubert L (see Verstuyft et al). 2003;73:51-60

E

- Echizen H (see Takahashi et al). 2003;73:253-63
Eddington ND (see Dowling et al). 2003;73:427-34
Eichelbaum M (see Drescher et al). 2003;73:223-31
Ekblad U (see Heikkinen et al). 2003;73:330-7
El Morabet H (see Verstuyft et al). 2003;73:51-60
Erb K (see Hermann et al). 2003;73:61-70
Evans WE (see Dervieux et al). 2003;73:506-16

F

- Fattinger K (see Csajka et al). 2003;73:20-30
Fellay J (see Csajka et al). 2003;73:20-30
Ferron GM (see Hermann et al). 2003;73:61-70
Fink JC (see Dowling et al). 2003;73:427-34
Flexner C (see Hamzeh et al). 2003;73:159-69
Flexner C (see Washington et al). 2003;73:406-16
Frame B (see Miller et al). 2003;73:491-505
Fromm MF (see Drescher et al). 2003;73:223-31
Frye RF (see Carcillo et al). 2003;73:456-67
Frye RF (see Chalon et al). 2003;73:178-91
Funck-Brentano C (see Démolis et al). 2003;73:242-52
Funck-Brentano C (see Verstuyft et al). 2003;73:51-60
Furukawa H (see Watanabe et al). 2003;73:435-55

G

- Gaedigk A, Ndjountché L, Gaedigk R, Bradford LD, Leeder JS. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects. 2003;73:575-6 (Letter)
Gaedigk R (see Gaedigk et al). 2003;73:575-6 (Letter)
Gaitonde M (see Barst et al). 2003;73:372-82
Gardiner SJ, Kirkpatrick CMJ, Begg EJ, Zhang M, Moore MP, Saville DJ. Transfer of metformin into human milk. 2003;73:71-7
Garnick MB (see Wong et al). 2003;73:304-11
Garofalo E (see Miller et al). 2003;73:491-505
Gebrekál AB (see Dreisbach et al). 2003;73:475-7 (Letter)
Geisslinger G (see Skarke et al). 2003;73:107-21
Geisslinger G (see Tegeder et al). 2003;73:417-26
Gerber J (see Hamzeh et al). 2003;73:159-69
Glaeser H (see Drescher et al). 2003;73:223-31
Gleiter CH (see Wagner et al). 2003;73:272-4 (Letter)
Golnez J-L (see Chalon et al). 2003;73:178-91
Gonzales CR (see Skinner et al). 2003;73:170-7

- Goodman DB (see Noel et al). 2003;73:292-303
Graff J (see Klinkhardt et al). 2003;73:232-41
Grass P (see Comets et al). 2003;73:95-106
Greim C (see Wagner et al). 2003;73:272-4 (Letter)
Guillaume C (see Stolk and Guillaume). 2003;73:131 (Letter)
Gupta SK (see Kang et al). 2003;73:31-40
Gurwitz JH (see Simon and Gurwitz). 2003;73:387-93 (Commentary)

H

- Haas DW (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
Haefeli WE (see Tayrouz et al). 2003;73:397-405
Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. 2003;73:122-30
Halushka PV (see Halushka et al). 2003;73:122-30
Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C, AIDS Clinical Trials Group 365 Study Team. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. 2003;73:159-69
Hancock ML (see Dervieux et al). 2003;73:506-16
Hanes DS (see Dowling et al). 2003;73:427-34
Harder S (see Klinkhardt et al). 2003;73:232-41
Harris PA (see Sofowora et al). 2003;73:366-71
Haruyama H (see Watanabe et al). 2003;73:435-55
Haughey DB (see Rogers et al). 2003;73:153-8 (Commentary)
Hebert MF (see Park et al). 2003;73:543-53
Heide L (see Wagner et al). 2003;73:272-4 (Letter)
Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. 2003;73:330-7
Henrich WL (see Dowling et al). 2003;73:427-34
Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, Paul J, Richards L, Cnota H-P, Troy S. Effects of age and sex on the disposition of retigabine. 2003;73:61-70
Higuchi S (see Nishizato et al). 2003;73:554-65
Hirota T (see Nishizato et al). 2003;73:554-65
Hitzl M (see Drescher et al). 2003;73:223-31
Hoffer C (see Kharasch et al). 2003;73:199-208
Hoppel CL (see Brass et al). 2003;73:338-47
Hoppe-Tichy T (see Tayrouz et al). 2003;73:397-405
Horsmans Y (see Chalon et al). 2003;73:178-91
Huang S-L (see Chen et al). 2003;73:264-71
Huang Z (see Chen et al). 2003;73:264-71
Hulgán T (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
Hunt TL (see Noel et al). 2003;73:292-303

I

- Ieiri I (see Nishizato et al). 2003;73:554-65
Innocenti F (see Sawyer et al). 2003;73:566-74
Irie S (see Nishizato et al). 2003;73:554-65
Ivy D (see Barst et al). 2003;73:372-82
Izumi T (see Watanabe et al). 2003;73:435-55

J

- Jaillon P (see Verstuyft et al). 2003;73:51-60
Japa S (see Dreisbach et al). 2003;73:475-7 (Letter)
Jönsson S, Karlsson MO. A rational approach for selection of optimal covariate-based dosing strategies. 2003;73:7-19

K

- Kalhom TF (see Park et al). 2003;73:543-53
Kalow W. Medical practice, race, and drug use. 2003;73:132-4 (Letter)
Kamath BL (see Dreisbach et al). 2003;73:475-7 (Letter)
Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. 2003;73:31-40
Karlsson MO (see Jönsson and Karlsson). 2003;73:7-19
Karyekar CS (see Dowling et al). 2003;73:427-34

- Kashima T (see Takahashi et al). 2003;73:253-63
Kashuba ADM (see Lowry et al). 2003;73:209-22
Kawabata K (see Nishizato et al). 2003;73:554-65
Kawai R (see Comets et al). 2003;73:95-106
Kawano T (see Obase et al). 2003;73:468-74
Kearns GL (see Koren et al). 2003;73:147-52 (Commentary)
Kearns GL (see Lowry et al). 2003;73:209-22
Kerb R (see Verstuyft et al). 2003;73:51-60
Khan IS (see Lowry et al). 2003;73:209-22
Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and mitotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P450A activity. 2003;73:199-208
Kim RB (see Dresser et al). 2003;73:41-50
Kim RB (see Sofowora et al). 2003;73:366-71
Kim RB (see Takahashi et al). 2003;73:253-63
Kim RB (see Wandel et al). 2003;73:394-6 (Commentary)
Kimko HC (see Lee et al). 2003;73:348-65
Kimura M (see Nishizato et al). 2003;73:554-65
Kimura S (see Takahashi et al). 2003;73:253-63
Kinoshita M (see Obase et al). 2003;73:468-74
Kirkpatrick CMJ (see Gardiner et al). 2003;73:71-7
Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. 2003;73:232-41
Knadler MP (see Skinner et al). 2003;73:170-7
Knebel N (see Hermann et al). 2003;73:61-70
Knoll C (see Carcillo et al). 2003;73:456-67
Koga T (see Watanabe et al). 2003;73:435-55
Kohno S (see Obase et al). 2003;73:468-74
Koishi R (see Watanabe et al). 2003;73:435-55
Koren G, Kearns GL, Reed M, Pons G. Use of healthy children as volunteers in drug studies: the ethical debate. 2003;73:147-52 (Commentary)
Kovács AF (see Tegeder et al). 2003;73:417-26
Krecic-Shepard ME (see Kang et al). 2003;73:31-40
Kuan H-Y (see Skinner et al). 2003;73:170-7
Kusuhara H (see Nishizato et al). 2003;73:554-65
Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. 2003;73:538-44
- L**
- Laine K (see Heikkinen et al). 2003;73:330-7
Laitila J (see Lilja et al). 2003;73:192-8
Lalonde R (see Miller et al). 2003;73:491-505
Lau DT-W (see Wong et al). 2003;73:304-11
Laufer S (see Wagner et al). 2003;73:272-4 (Letter)
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. 2003;73:348-65
Lee J (see Hamzeh et al). 2003;73:159-69
Leeder JS (see Gaedigk et al). 2003;73:575-6 (Letter)
Leeder JS (see Lowry et al). 2003;73:209-22
Lertora JLL (see Dreisbach et al). 2003;73:475-7 (Letter)
Lesko LJ (see Rolan et al). 2003;73:284-91 (Commentary)
Levy AE (see Park et al). 2003;73:543-53
Levy M, Reidenberg MM. What has been the impact of the concept of essential drugs? 2003;73:275-8 (Commentary)
Light PD (see Dowling et al). 2003;73:427-34
Lilja JJ, Backman JT, Laitila J, Lurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of cefiprolol. 2003;73:192-8
Lim M (see Skinner et al). 2003;73:170-7
Lin YS (see Park et al). 2003;73:543-53
Lindhoff-Last E (see Klinkhardt et al). 2003;73:232-41
Long AJ (see Chalon et al). 2003;73:178-91
Lötsch J (see Skarke et al). 2003;73:107-21
Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba ADM, Schuetz EG, Bertino JS Jr, van den Anker JN, Leeder JS. Cisapride:

- a potential model substrate to assess cytochrome P450A4 activity in vivo. 2003;73:209-22
Lurila H (see Lilja et al). 2003;73:192-8

M

- Marbach P (see Comets et al). 2003;73:95-106
Marsh CL (see Park et al). 2003;73:543-53
Martin PD (see Cooper et al). 2003;73:322-9
Marzolini C (see Csajka et al). 2003;73:20-30
Matsuse H (see Obase et al). 2003;73:468-74
Matsushita Y (see Watanabe et al). 2003;73:435-55
Mayer MD (see Brass et al). 2003;73:338-47
McCrea J (see Hamzeh et al). 2003;73:159-69
Menchaca D (see Wong et al). 2003;73:304-11
Mentré F (see Comets et al). 2003;73:95-106
Mikus G (see Tayrouz et al). 2003;73:397-405
Miller R, Frame B, Corrigan B, Burger P, Bockbrader H, Garofalo E, Lalonde R. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. 2003;73:491-505
Mirghani RA (see Christensen et al). 2003;73:517-28
Mitsuta-Izaki K (see Obase et al). 2003;73:468-74
Miyoshi K (see Watanabe et al). 2003;73:435-55
Modi NB (see Kang et al). 2003;73:31-40
Moore MP (see Gardiner et al). 2003;73:71-7
Mouton JW (see de Hoog et al). 2003;73:131-2 (Letter reply)
Mowry SE (see Dreisbach et al). 2003;73:475-7 (Letter)
Muirhead GJ (see Christensen et al). 2003;73:517-28
Mulder AB, van den Bergh FAJTM, Vermes I. Response to "The efficacy of simvastatin is not influenced by CYP2D6 polymorphism" by Geisel et al. 2003;73:475 (Letter)
Mulford DJ (see Brass et al). 2003;73:338-47
Mürdt T (see Drescher et al). 2003;73:223-31
Muszkat M (see Sofowora et al). 2003;73:366-71
Muszkat M (see Takahashi et al). 2003;73:253-63

N

- Nafziger AN (see Lowry et al). 2003;73:209-22
Nair UB (see Sofowora et al). 2003;73:366-71
Nakamura K (see Watanabe et al). 2003;73:435-55
Natarajan J (see Noel et al). 2003;73:292-303
Ndjountché L (see Gaedigk et al). 2003;73:575-6 (Letter)
Nestorov I (see Lee et al). 2003;73:348-65
Neuvonen M (see Kyrklund et al). 2003;73:538-44
Neuvonen PJ (see Kyrklund et al). 2003;73:538-44
Neuvonen PJ (see Lilja et al). 2003;73:192-8
Nguyen N (see Barst et al). 2003;73:372-82
Nicotera J (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. Polymorphisms of *OATP-C (SLC22A6)* and *OAT3 (SLC22A8)* genes: consequences for pravastatin pharmacokinetics. 2003;73:554-65
Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. 2003;73:292-303
Nordmark A (see Christensen et al). 2003;73:517-28

O

- Obase Y, Shimoda T, Kawano T, Saeki S, Tomari S-y, Mitsuta-Izaki K, Matsuse H, Kinoshita M, Kohno S. Polymorphisms in the *CYP1A2* gene and theophylline metabolism in patients with asthma. 2003;73:468-74
Otsubo K (see Nishizato et al). 2003;73:554-65
Ou-Yang D-S (see Chen et al). 2003;73:264-71

P

- Palo P (see Heikkinen et al). 2003;73:330-7
Pan A (see Skinner et al). 2003;73:170-7

- Pantle-Fisher FH (see Sawyer et al). 2003;73:566-74
 Park JM, Lin YS, Calamia JC, Thummel KE, Slattery JT, Kalhorn TF, Carithers RL Jr, Levy AE, Marsh CL, Hebert MF. Transiently altered acetaminophen metabolism after liver transplantation. 2003;73:543-53
 Paul J (see Hermann et al). 2003;73:61-70
 Peck CC, Rubin DB, Sheiner LB. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. 2003;73:481-90 (Commentary)
 Peck CC (see Lee et al). 2003;73:348-65
 Pei D (see Sawyer et al). 2003;73:566-74
 Pickkers P (see de Hoon et al). 2003;73:312-21
 Pons G (see Koren et al). 2003;73:147-52 (Commentary)
 Prasad HC (see Sofowora et al). 2003;73:366-71
 Price J (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
 Pui C-H (see Dervieux et al). 2003;73:506-16

Q

- Quick JD. Ensuring access to essential medicines in the developing countries: a framework for action. 2003;73:279-83 (Commentary)

R

- Raffanti S (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
 Rajpal A, Reidenberg MM. Drug labeling should be kept current. 2003;73:4-6 (Commentary)
 Ramirez J (see Sawyer et al). 2003;73:566-74
 Ratain MJ (see Sawyer et al). 2003;73:566-74
 Ratnam KK (see Donahue et al). 2003;73:78-86. Correction 2003;73:576
 Reddy S (see Skinner et al). 2003;73:170-7
 Reed M (see Koren et al). 2003;73:147-52 (Commentary)
 Reidenberg JW. The need to consider the cost factor of drugs in clinical trials. 2003;73:477-8 (Letter)
 Reidenberg MM (see Levy and Reidenberg). 2003;73:275-8 (Commentary)
 Reidenberg MM (see Rajpal and Reidenberg). 2003;73:4-6 (Commentary)
 Relling MV (see Dervieux et al). 2003;73:506-16
 Rettie AE (see Dreisbach et al). 2003;73:475-7 (Letter)
 Ribeiro RC (see Dervieux et al). 2003;73:506-16
 Richards L (see Hermann et al). 2003;73:61-70
 Riedel K-D (see Tayrouz et al). 2003;73:397-405
 Rivera GK (see Dervieux et al). 2003;73:506-16
 Rocci ML Jr (see Rogers et al). 2003;73:153-8 (Commentary)
 Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. 2003;73:153-8 (Commentary)
 Rogge M (see Lee et al). 2003;73:348-65
 Rolan P, Atkinson AJ Jr, Lesko LJ, Scientific Organizing Committee and Conference Report Committee. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. 2003;73:284-91 (Commentary)
 Romkes M (see Carcillo et al). 2003;73:456-67
 Rosenkranz SL (see Washington et al). 2003;73:406-16
 Roskos L (see Carcillo et al). 2003;73:456-67
 Ruan P (see Hamzeh et al). 2003;73:159-69
 Rubin DB (see Peck et al). 2003;73:481-90 (Commentary)
 Ruus P (see Hermann et al). 2003;73:61-70

S

- Saeki S (see Obase et al). 2003;73:468-74
 Sandlund JT (see Dervieux et al). 2003;73:506-16
 Sathirakul K (see Skinner et al). 2003;73:170-7
 Sauer J-M (see Chalon et al). 2003;73:178-91
 Saville DJ (see Gardiner et al). 2003;73:71-7
 Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. 2003;73:566-74
 Schmidt H (see Skarke et al). 2003;73:107-21

- Schmitt K (see Barst et al). 2003;73:372-82
 Schneck DW (see Cooper et al). 2003;73:322-9
 Schuetz EG (see Lowry et al). 2003;73:209-22
 Schwartz JB (see Kang et al). 2003;73:31-40
 Schwarz UI (see Dresser et al). 2003;73:41-50
 Scientific Organizing Committee and Conference Report Committee (see Rolan et al). 2003;73:284-91 (Commentary)
 Seegel M (see Tegeder et al). 2003;73:417-26
 Segal Y (see Washington et al). 2003;73:406-16
 Sereika S (see Carcillo et al). 2003;73:456-67
 Sheffels P (see Kharasch et al). 2003;73:199-208
 Sheiner LB (see Peck et al). 2003;73:481-90 (Commentary)
 Sheiner LB (see Washington et al). 2003;73:406-16
 Shimizu M (see Watanabe et al). 2003;73:435-55
 Shimoda T (see Obase et al). 2003;73:468-74
 Simon SR, Gurwitz JH. Drug therapy in the elderly: improving quality and access. 2003;73:387-93 (Commentary)
 Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. 2003;73:107-21
 Skinner MH, Kuan H-Y, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. 2003;73:170-7
 Slattery JT (see Park et al). 2003;73:543-53
 Smith BP (see Chalon et al). 2003;73:178-91
 Smits P (see de Hoon et al). 2003;73:312-21
 Sofowora GG, Dishy V, Muskat M, Xie HG, Kim RB, Harris PA, Prasad HC, Byrne DW, Nair UB, Wood AJJ, Stein CM. A common β_1 -adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β -blockade. 2003;73:366-71
 Stackiewicz L (see Dowling et al). 2003;73:427-34
 Stein CM. Clinical Pharmacology & Therapeutics—an update. 2003;73:1-3 (Commentary)
 Stein CM (see Sofowora et al). 2003;73:366-71
 Stein CM (see Wandel et al). 2003;73:394-6 (Commentary)
 Stickler TK (see Brass et al). 2003;73:338-47
 Stolk LM, Guillaume C. Routine early therapeutic drug monitoring is necessary during the first week of life. 2003;73:131 (Letter)
 Strabach S (see Verstuyft et al). 2003;73:51-60
 Struijker-Boudier HAJ (see de Hoon et al). 2003;73:312-21
 Sugawara M (see Watanabe et al). 2003;73:435-55
 Sugiyama Y (see Nishizato et al). 2003;73:554-65
 Suzuki H (see Nishizato et al). 2003;73:554-65

T

- Takahashi H, Wilkinson GR, Caraco Y, Muskat M, Kim RB, Kashima T, Kimura S, Echizen H. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. 2003;73:253-63
 Takahashi T (see Watanabe et al). 2003;73:435-55
 Takane H (see Nishizato et al). 2003;73:554-65
 Tan Z-R (see Chen et al). 2003;73:264-71
 Tayrouz Y, Ding R, Burhenne J, Riedel K-D, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. Pharmacokinetic and pharmacologic interaction between digoxin and Cremophor RH40. 2003;73:397-405
 Tegeder I, Bräutigam L, Seegel M, Al-Dam A, Turowski B, Geisslinger G, Kovács AF. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. 2003;73:417-26
 Telenti A (see Csajka et al). 2003;73:20-30
 Thomasson HR (see Chalon et al). 2003;73:178-91
 Thummel K (see Carcillo et al). 2003;73:456-67
 Thummel KE (see Park et al). 2003;73:543-53
 Tomari S-y (see Obase et al). 2003;73:468-74
 Tomita A (see Watanabe et al). 2003;73:435-55
 Troy S (see Hermann et al). 2003;73:61-70
 Trugnan G (see Verstuyft et al). 2003;73:51-60
 Turowski B (see Tegeder et al). 2003;73:417-26
 Tybring G (see Christensen et al). 2003;73:517-28

U

- Unutmaz D (*see* Donahue et al). 2003;73:78-86. Correction 2003;73:576
Urae A (*see* Nishizato et al). 2003;73:554-65
Urasaki Y (*see* Nishizato et al). 2003;73:554-65

V

- Vacheron F (*see* Démolis et al). 2003;73:242-52
Van Bortel LMAB (*see* de Hoon et al). 2003;73:312-21
van den Anker JN (*see* de Hoog et al). 2003;73:131-2 (Letter reply)
van den Anker JN (*see* Lowry et al). 2003;73:209-22
van den Bergh FAJTM (*see* Mulder et al). 2003;73:475 (Letter)
van Giersbergen PLM (*see* Barst et al). 2003;73:372-82
Venkataramanan R (*see* Carcillo et al). 2003;73:456-67
Vermes I (*see* Mulder et al). 2003;73:475 (Letter)
Verotta D (*see* Kang et al). 2003;73:31-40
Verstuyft C, Strabach S, El Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Trugnan G, Becquemont L. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. 2003;73:51-60
Verweij J. Concern about similarity of manuscripts. 2003;73:274 (Letter)
Voelker JR (*see* Benson and Voelker). 2003;73:87-94
Vonderscher J (*see* Comets et al). 2003;73:95-106

W

- Wagner I, Greim C, Laufer S, Heide L, Gleiter CH. Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor α or interleukin 1 β release in vitro and ex vivo. 2003;73:272-4 (Letter)
Wahlberg A (*see* Christensen et al). 2003;73:517-28
Walker A (*see* Kharasch et al). 2003;73:199-208
Walker LP (*see* Halushka et al). 2003;73:122-30
Wandel C, Kim RB, Stein CM. "Inactive" excipients such as Cremophor can affect in vivo drug disposition. 2003;73:394-6 (Commentary)
Wang D (*see* Lee et al). 2003;73:348-65
Warwick MJ (*see* Cooper et al). 2003;73:322-9
Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF. AIDS Clinical Trials Group Protocol 378 (ACTG 378) Study

- Team. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. 2003;73:406-16
Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasuno H, Koishi R, Takahashi T, Miyoshi K, Nakamura K, Izumi T, Matsushita Y, Furukawa H, Haruyama H, Koga T. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. 2003;73:435-55
Weir MR (*see* Dowling et al). 2003;73:427-34
Weiss J (*see* Tayrouz et al). 2003;73:397-405
Widlitz A (*see* Barst et al). 2003;73:372-82
Wilkinson GR (*see* Dresser et al). 2003;73:41-50
Wilkinson GR (*see* Takahashi et al). 2003;73:253-63
Wilson JW (*see* Carcillo et al). 2003;73:456-67
Wise SD (*see* Skinner et al). 2003;73:170-7
Witcher J (*see* Chalon et al). 2003;73:178-91
Wong SL, Lau DT-W, Baughman SA, Menchaca D, Garnick MB. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. 2003;73:304-11
Wood AJJ (*see* Sofowora et al). 2003;73:366-71
Wright C (*see* Sawyer et al). 2003;73:566-74
Wu H (*see* Hamzeh et al). 2003;73:159-69

X

- Xie HG (*see* Sofowora et al). 2003;73:366-71

Y

- Yaşar Ü (*see* Christensen et al). 2003;73:517-28
Yasuno H (*see* Watanabe et al). 2003;73:435-55
Yeo KP (*see* Skinner et al). 2003;73:170-7

Z

- Zhang M (*see* Gardiner et al). 2003;73:71-7
Zhou H-H (*see* Chen et al). 2003;73:264-71

Subject index*

A

Abarelix

Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer (Wong et al). 2003;73:304-11

Abstracts

Abstracts. 2003;73:P1-126

Accessibility to health services; see Health services accessibility

Acetaminophen

Transiently altered acetaminophen metabolism after liver transplantation (Park et al). 2003;73:543-53

Acromegaly

Population pharmacodynamic analysis of octreotide in acromegalic patients (Comets et al). 2003;73:95-106

Administration, oral

Disposition and mitotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity (Kharasch et al). 2003;73:199-208

African Americans

Discovery of a novel nonfunctional cytochrome P450 2D6 allele, *CYP2D6**42, in African American subjects (Gaedigk et al). 2003;73:575-6 (Letter)

Age factors

Effects of age and sex on the disposition of retigabine (Hermann et al). 2003;73:61-70

Aged

Drug therapy in the elderly: improving quality and access (Simon and Gurwitz). 2003;73:387-93 (Commentary)

Alfentanil

Disposition and mitotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity (Kharasch et al). 2003;73:199-208

Alleles

Discovery of a novel nonfunctional cytochrome P450 2D6 allele, *CYP2D6**42, in African American subjects (Gaedigk et al). 2003;73:575-6 (Letter)

American Society for Clinical Pharmacology and Therapeutics

A message from the ASCPT membership committee chairperson. 2003;73:135

A message from the ASCPT membership committee chairperson. 2003;73:479-80

2003 Annual Meeting Program. 2003;73:136-46

Analgesia

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers (Skarke et al). 2003;73:107-21

Anti-infective agents, fluoroquinolone

Effects of three fluoroquinolones on QT interval in healthy adults after single doses (Noel et al). 2003;73:292-303

Antihypertensive agents

Drug labeling should be kept current (Rajpal and Reidenberg). 2003;73:4-6 (Commentary)

Antiviral agents

Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy (Donahue et al). 2003;73:78-86. Correction 2003;73:576

*January, pp. 1-146; February, pp. P1-P126; March, pp. 147-274; April, pp. 275-386; May, pp. 387-480; June, pp. 481-590. Index to the ASCPT meeting abstracts is located in the February issue.

Aspirin

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Genetic variation in cyclooxygenase 1: effects on response to aspirin (Halushka et al). 2003;73:122-30

Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects (Chen et al). 2003;73:264-71

Asthma

Polymorphisms in the *CYP1A2* gene and theophylline metabolism in patients with asthma (Obase et al). 2003;73:468-74

Atherosclerosis

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Atomoxetine

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites (Chalon et al). 2003;73:178-91

B

Bergamottin

Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice (Bailey et al). 2003;73:529-37

Beta adrenergic receptors; see Receptors, adrenergic, beta

Beverages

Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice (Bailey et al). 2003;73:529-37

Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of cefiprolol (Lilja et al). 2003;73:192-8

Biliary tract

P-glycoprotein-mediated intestinal and biliary digoxin transport in humans (Drescher et al). 2003;73:223-31

Biological availability

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition (Verstuyft et al). 2003;73:51-60

Biomarkers

Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development (Rolan et al). 2003;73:284-91 (Commentary)

Blood platelets

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Blood pressure

A common β_1 -adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β -blockade (Sofowora et al). 2003;73:366-71

Books

Books received. 2003;73:383

Bosentan

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (Barst et al). 2003;73:372-82

Breast feeding

Transfer of metformin into human milk (Gardiner et al). 2003;73:71-7

C

Caffeine

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28

Calcitonin gene-related peptide

Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans (de Hoon et al). 2003;73:312-21

Calcium

Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin (Benson and Voelker). 2003;73:87-94

Carnitine

Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil (Brass et al). 2003;73:338-47

Castor oil

"Inactive" excipients such as Cremophor can affect in vivo drug disposition (Wandel et al). 2003;73:394-6 (Commentary)

Pharmacokinetic and pharmacologic interaction between digoxin and Cremophor RH40 (Tayrouz et al). 2003;73:397-405

Caucasian Americans; see White Americans

Causality

Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval (Peck et al). 2003;73:481-90 (Commentary)

Cefditoren

Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil (Brass et al). 2003;73:338-47

Celiprolol

Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol (Lilja et al). 2003;73:192-8

Child

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (Barst et al). 2003;73:372-82

Ciprofloxacin

Effects of three fluoroquinolones on QT interval in healthy adults after single doses (Noel et al). 2003;73:292-303

Cisapride

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo (Lowry et al). 2003;73:209-22

Cisplatin

Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer (Tegeder et al). 2003;73:417-26

Clinical Pharmacology & Therapeutics

Clinical Pharmacology & Therapeutics—an update (Stein). 2003;73:1-3 (Commentary)

Concern about similarity of manuscripts (Verweij). 2003;73:274 (Letter)

Clinical trial

Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval (Peck et al). 2003;73:481-90 (Commentary)

The need to consider the cost factor of drugs in clinical trials (Reidenberg). 2003;73:477-8 (Letter)

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (Barst et al). 2003;73:372-82

Clopidogrel

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Commentaries

Commentaries. 2003;73:1-6, 147-58, 275-91, 387-96, 481-90

Corrections

A comparison of three methods for predicting lithium doses in Chinese psychiatric patients (Chang et al) (2003;73:P88). 2003;73:565

Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy (Donahue et al) (2003;73:78-86). 2003;73:576

Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam (Lemmens et al) (1995;58:567-82). 2003;73:271

Correspondence; see Letters to the Editor

Cost of drugs; see Drug costs

Cremophor; see Castor oil

Cyclooxygenase; see Prostaglandin-endoperoxide synthase

Cyclosporine

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50

Cytochrome P450

Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice (Bailey et al). 2003;73:529-37

Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease (Dowling et al). 2003;73:427-34

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo (Lowry et al). 2003;73:209-22

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50

Coordinated intrahepatic and extrahepatic regulation of cytochrome P4502D6 in healthy subjects and in patients after liver transplantation (Carcillo et al). 2003;73:456-67

Cytochrome P4502C9 activity in end-stage renal disease (Dreisbach et al). 2003;73:475-7 (Letter)

Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects (Gaedigk et al). 2003;73:575-6 (Letter)

Disposition and mitotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity (Kharasch et al). 2003;73:199-208

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers (Skinner et al). 2003;73:170-7

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity (Rogers et al). 2003;73:153-8 (Commentary)

Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects (Chen et al). 2003;73:264-71

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28

D

Debrisoquin

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28

Delayed-action preparations

Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking (Kang et al). 2003;73:31-40

Desipramine

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers (Skinner et al). 2003;73:170-7

Developing countries

Ensuring access to essential medicines in the developing countries: a framework for action (Quick). 2003;73:279-83 (Commentary)

Diabetes mellitus, non-insulin-dependent

A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus (Watanabe et al). 2003;73:435-55

Digoxin

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition (Verstuyft et al). 2003;73:51-60

"Inactive" excipients such as Cremophor can affect in vivo drug disposition (Wandel et al). 2003;73:394-6 (Commentary)

P-glycoprotein-mediated intestinal and biliary digoxin transport in humans (Drescher et al). 2003;73:223-31

Pharmacokinetic and pharmacologic interaction between digoxin and Cremophor RH40 (Tayrouz et al). 2003;73:397-405

Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin (Benson and Voelker). 2003;73:87-94

Dipyridamole

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition (Verstuyft et al). 2003;73:51-60

Dose-response relationship, drug

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites (Chalon et al). 2003;73:178-91

- Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors (Washington et al). 2003;73:406-16
- Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects (Démolis et al). 2003;73:242-52
- Effects of three fluoroquinolones on QT interval in healthy adults after single doses (Noel et al). 2003;73:292-303
- Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures (Miller et al). 2003;73:491-505
- A rational approach for selection of optimal covariate-based dosing strategies (Jönsson and Karlsson). 2003;73:7-19
- Drug approval**
Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval (Peck et al). 2003;73:481-90 (Commentary)
- Drug costs**
Ensuring access to essential medicines in the developing countries: a framework for action (Quick). 2003;73:279-83 (Commentary)
The need to consider the cost factor of drugs in clinical trials (Reidenberg). 2003;73:477-8 (Letter)
What has been the impact of the concept of essential drugs? (Levy and Reidenberg). 2003;73:275-8 (Commentary)
- Drug design**
Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development (Rolan et al). 2003;73:284-91 (Commentary)
- Drug interactions**
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50
Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition (Verstuyft et al). 2003;73:51-60
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors (Washington et al). 2003;73:406-16
Genetic variation in cyclooxygenase 1: effects on response to aspirin (Halushka et al). 2003;73:122-30
"Inactive" excipients such as Cremophor can affect in vivo drug disposition (Wandel et al). 2003;73:394-6 (Commentary)
Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects (Chen et al). 2003;73:264-71
Pharmacokinetic and pharmacologic interaction between digoxin and Cremophor RH40 (Tayrouz et al). 2003;73:397-405
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin (Hamzeh et al). 2003;73:159-69
Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin (Benson and Voelker). 2003;73:87-94
- Drug labeling**
Drug labeling should be kept current (Rajpal and Reidenberg). 2003;73:4-6 (Commentary)
- Drug monitoring**
Routine early therapeutic drug monitoring is necessary during the first week of life (Stolk and Guillaume) (Letter); (de Hoog et al) (Reply). 2003;73:131-2
- Drug studies; see Research**
- Drug therapy**
Drug therapy in the elderly: improving quality and access (Simon and Gurwitz). 2003;73:387-93 (Commentary)
- Drug utilization**
Medical practice, race, and drug use (Kalow). 2003;73:132-4 (Letter)
- Drugs, essential**
Ensuring access to essential medicines in the developing countries: a framework for action (Quick). 2003;73:279-83 (Commentary)
What has been the impact of the concept of essential drugs? (Levy and Reidenberg). 2003;73:275-8 (Commentary)
- Duloxetine**
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers (Skinner et al). 2003;73:170-7

E**Efavirenz**

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection (Csajka et al). 2003;73:20-30

Effectiveness of treatment; see Treatment outcome**Electrocardiography**

Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects (Démolis et al). 2003;73:242-52

Effects of three fluoroquinolones on QT interval in healthy adults after single doses (Noel et al). 2003;73:292-303

Embolization, therapeutic

Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer (Tegeder et al). 2003;73:417-26

End-stage renal disease; see Kidney failure, chronic**Enzymes**

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28

Essential drugs; see Drugs, essential**Etanercept**

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis (Lee et al). 2003;73:348-65

Ethics

Use of healthy children as volunteers in drug studies: the ethical debate (Koren et al). 2003;73:147-52 (Commentary)

Ethnic groups

Medical practice, race, and drug use (Kalow). 2003;73:132-4 (Letter)

Excipients

"Inactive" excipients such as Cremophor can affect in vivo drug disposition (Wandel et al). 2003;73:394-6 (Commentary)

F**Fexofenadine**

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50

First week of life; see Infant, newborn**Fluoxetine**

Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation (Heikkinen et al). 2003;73:330-7

G**Gemfibrozil**

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance (Kyrklund et al). 2003;73:538-44

Genes

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50

Polymorphisms in the *CYP1A2* gene and theophylline metabolism in patients with asthma (Obase et al). 2003;73:468-74

Polymorphisms of *OATP-C (SLC21A6)* and *OAT3 (SLC22A8)* genes: consequences for pravastatin pharmacokinetics (Nishizato et al). 2003;73:554-65

Genetics

A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus (Watanabe et al). 2003;73:435-55

Genome

Population differences in *S-warfarin* metabolism between *CYP2C9* genotype-matched Caucasian and Japanese patients (Takahashi et al). 2003;73:253-63

Genotype

Population differences in *S-warfarin* metabolism between *CYP2C9* genotype-matched Caucasian and Japanese patients (Takahashi et al). 2003;73:253-63

Glucuronates

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers (Skarke et al). 2003;73:107-21

Glucuronosyltransferase

A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine (Sawyer et al). 2003;73:566-74

Glycoproteins

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo (Lowry et al). 2003;73:209-22

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition (Verstuyft et al). 2003;73:51-60

Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy (Donahue et al). 2003;73:78-86. Correction 2003;73:576

P-glycoprotein-mediated intestinal and biliary digoxin transport in humans (Drescher et al). 2003;73:223-31

Gonadorelin

Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer (Wong et al). 2003;73:304-11

Grapefruit juice; see Beverages

Guest reviewers

Guest reviewers. 2003;73:384-6

H

Health services accessibility

Drug therapy in the elderly: improving quality and access (Simon and Gurwitz). 2003;73:387-93 (Commentary)

Ensuring access to essential medicines in the developing countries: a framework for action (Quick). 2003;73:279-83 (Commentary)

What has been the impact of the concept of essential drugs? (Levy and Reidenberg). 2003;73:275-8 (Commentary)

Hepatotoxicity; see Liver, toxicity

HIV

Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy (Donahue et al). 2003;73:78-86. Correction 2003;73:576

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection (Csajka et al). 2003;73:20-30

Homeostasis

Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil (Brass et al). 2003;73:338-47

Hypericum perforatum

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50

Hypertension

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (Barst et al). 2003;73:372-82

I

Indinavir

Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin (Hamzeh et al). 2003;73:159-69

Infant, newborn

Routine early therapeutic drug monitoring is necessary during the first week of life (Stolk and Guillaume) (Letter); (de Hoog et al) (Reply). 2003;73:131-2

Infusions, intra-arterial

Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer (Tegeder et al). 2003;73:417-26

Infusions, intravenous

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity (Rogers et al). 2003;73:153-8 (Commentary)

Infusions, subcutaneous

Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer (Wong et al). 2003;73:304-11

Interactions, drug; see Drug interactions

Interleukin-1

Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor α or interleukin 1 β release in vitro and ex vivo (Wagner et al). 2003;73:272-4 (Letter)

Intestines

P-glycoprotein-mediated intestinal and biliary digoxin transport in humans (Drescher et al). 2003;73:223-31

Isoenzymes

Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects (Chen et al). 2003;73:264-71

Itraconazole

Effect of itraconazole on the pharmacokinetics of rosuvastatin (Cooper et al). 2003;73:322-9

Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of cefiprolol (Lilja et al). 2003;73:192-8

J

Japan

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients (Takahashi et al). 2003;73:253-63

A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus (Watanabe et al). 2003;73:435-55

Journal of Clinical Oncology

Concern about similarity of manuscripts (Verweij). 2003;73:274 (Letter)

K

Kidney

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance (Kyrklund et al). 2003;73:538-44

Kidney failure, chronic

Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease (Dowling et al). 2003;73:427-34

Cytochrome P4502C9 activity in end-stage renal disease (Dreisbach et al). 2003;73:475-7 (Letter)

Kidney function tests

Effects of age and sex on the disposition of retigabine (Hermann et al). 2003;73:61-70

L

Lactation

Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation (Heikkinen et al). 2003;73:330-7

Letters to the Editor

Concern about similarity of manuscripts (Verweij). 2003;73:274

Cytochrome P4502C9 activity in end-stage renal disease (Dreisbach et al). 2003;73:475-7

Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects (Gaedigk et al). 2003;73:575-6

Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor α or interleukin 1 β release in vitro and ex vivo (Wagner et al). 2003;73:272-4

Medical practice, race, and drug use (Kalow). 2003;73:132-4

The need to consider the cost factor of drugs in clinical trials (Reidenberg). 2003;73:477-8

Response to "The efficacy of simvastatin is not influenced by CYP2D6 polymorphism" by Geisel et al (Mulder et al). 2003;73:475

Routine early therapeutic drug monitoring is necessary during the first week of life (Stolk and Guillaume) (Letter); (de Hoog et al) (Reply). 2003;73:131-2

Leukemia, lymphocytic

Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia (Derieux et al). 2003;73:506-16

Leukocytes

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Levofloxacin

Effects of three fluoroquinolones on QT interval in healthy adults after single doses (Noel et al). 2003;73:292-303

Lime juice; see Beverages**Liver**

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity (Rogers et al). 2003;73:153-8 (Commentary)

Liver, toxicity

A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus (Watanabe et al). 2003;73:435-55

Liver failure

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites (Chalon et al). 2003;73:178-91

Liver transplantation

Coordinated intrahepatic and extrahepatic regulation of cytochrome P4502D6 in healthy subjects and in patients after liver transplantation (Carcillo et al). 2003;73:456-67

Transiently altered acetaminophen metabolism after liver transplantation (Park et al). 2003;73:543-53

Logistic models

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis (Lee et al). 2003;73:348-65

Losartan

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28

Lymphocytes

Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia (Derieux et al). 2003;73:506-16

Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy (Donahue et al). 2003;73:78-86. Correction 2003;73:576

M**Manuscripts, medical**

Concern about similarity of manuscripts (Verweij). 2003;73:274 (Letter)

MDR1 gene; see Genes**Mercaptopurine**

Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia (Derieux et al). 2003;73:506-16

Metabolism

Polymorphisms in the *CYP1A2* gene and theophylline metabolism in patients with asthma (Obase et al). 2003;73:468-74

Transiently altered acetaminophen metabolism after liver transplantation (Park et al). 2003;73:543-53

Metformin

Transfer of metformin into human milk (Gardiner et al). 2003;73:71-7

Methotrexate

Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia (Derieux et al). 2003;73:506-16

Midazolam

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo (Lowry et al). 2003;73:209-22

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (Dresser et al). 2003;73:41-50

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity (Rogers et al). 2003;73:153-8 (Commentary)

Milk, human

Transfer of metformin into human milk (Gardiner et al). 2003;73:71-7

Miotics

Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity (Kharasch et al). 2003;73:199-208

Models, statistical

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers (Skarke et al). 2003;73:107-21

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo (Lowry et al). 2003;73:209-22

Morphine

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers (Skarke et al). 2003;73:107-21

A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine (Sawyer et al). 2003;73:566-74

Mouth neoplasms

Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer (Tegeder et al). 2003;73:417-26

Moxifloxacin

Effects of three fluoroquinolones on QT interval in healthy adults after single doses (Noel et al). 2003;73:292-303

N**Narcotics**

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers (Skarke et al). 2003;73:107-21

Nelfinavir

Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy (Donahue et al). 2003;73:78-86. Correction 2003;73:576

Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development

Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development (Rolan et al). 2003;73:284-91 (Commentary)

Norfluoxetine

Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation (Heikkinen et al). 2003;73:330-7

O**Octreotide**

Population pharmacodynamic analysis of octreotide in acromegalic patients (Comets et al). 2003;73:95-106

Omeprazole

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28

Oral administration; see Administration, oral**Oral cancer; see Mouth neoplasms****P****Pain**

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers (Skarke et al). 2003;73:107-21

Paroxetine

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers (Skinner et al). 2003;73:170-7

Pediatric patient; see Child**Pharmaceutical interactions; see Drug interactions****Pharmacodynamics**

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers (Skarke et al). 2003;73:107-21

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects (Démolis et al). 2003;73:242-52

Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-

- releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer (Wong et al). 2003;73:304-11
- Population pharmacodynamic analysis of octreotide in acromegalic patients (Comets et al). 2003;73:95-106
- Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis (Lee et al). 2003;73:348-65
- A rational approach for selection of optimal covariate-based dosing strategies (Jönsson and Karlsson). 2003;73:7-19
- Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin (Benson and Voelker). 2003;73:87-94
- Pharmacogenetics**
- Genetic variation in cyclooxygenase 1: effects on response to aspirin (Halushka et al). 2003;73:122-30
- Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects (Chen et al). 2003;73:264-71
- Medical practice, race, and drug use (Kalow). 2003;73:132-4 (Letter)
- A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine (Sawyer et al). 2003;73:566-74
- Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients (Takahashi et al). 2003;73:253-63
- Pharmacokinetics**
- Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo (Lowry et al). 2003;73:209-22
- Disposition and mitotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity (Kharasch et al). 2003;73:199-208
- Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers (Skinner et al). 2003;73:170-7
- Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites (Chalon et al). 2003;73:178-91
- Effect of itraconazole on the pharmacokinetics of rosuvastatin (Cooper et al). 2003;73:322-9
- Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors (Washington et al). 2003;73:406-16
- Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of cefiprolol (Lilja et al). 2003;73:192-8
- P-glycoprotein-mediated intestinal and biliary digoxin transport in humans (Drescher et al). 2003;73:223-31
- Pharmacokinetic and pharmacologic interaction between digoxin and Cremophor RH40 (Tayrouz et al). 2003;73:397-405
- Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation (Heikkinen et al). 2003;73:330-7
- Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer (Wong et al). 2003;73:304-11
- Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (Barst et al). 2003;73:372-82
- Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics (Nishizato et al). 2003;73:554-65
- Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis (Lee et al). 2003;73:348-65
- Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection (Csajka et al). 2003;73:20-30
- A rational approach for selection of optimal covariate-based dosing strategies (Jönsson and Karlsson). 2003;73:7-19
- Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin (Hamzeh et al). 2003;73:159-69
- Phenotype**
- An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity (Rogers et al). 2003;73:153-8 (Commentary)
- The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28
- Pivoxil**
- Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil (Brass et al). 2003;73:338-47
- Plants, medicinal**
- Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor α or interleukin 1 β release in vitro and ex vivo (Wagner et al). 2003;73:272-4 (Letter)
- Plasma**
- Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance (Kyrklund et al). 2003;73:538-44
- Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of cefiprolol (Lilja et al). 2003;73:192-8
- Platelets; see Blood platelets**
- Polymorphism**
- A common β_1 -adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β -blockade (Sofowora et al). 2003;73:366-71
- Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma (Obase et al). 2003;73:468-74
- Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics (Nishizato et al). 2003;73:554-65
- Response to "The efficacy of simvastatin is not influenced by CYP2D6 polymorphism" by Geisel et al (Mulder et al). 2003;73:475 (Letter)
- Population studies**
- Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking (Kang et al). 2003;73:31-40
- Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients (Takahashi et al). 2003;73:253-63
- Population pharmacodynamic analysis of octreotide in acromegalic patients (Comets et al). 2003;73:95-106
- Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis (Lee et al). 2003;73:348-65
- Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection (Csajka et al). 2003;73:20-30
- Pravastatin**
- Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance (Kyrklund et al). 2003;73:538-44
- Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics (Nishizato et al). 2003;73:554-65
- Pregabalin**
- Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures (Miller et al). 2003;73:491-505
- Pregnancy**
- Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation (Heikkinen et al). 2003;73:330-7
- Prodrugs**
- Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil (Brass et al). 2003;73:338-47
- Prostaglandin-endoperoxide synthase**
- Genetic variation in cyclooxygenase 1: effects on response to aspirin (Halushka et al). 2003;73:122-30
- Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor α or interleukin 1 β release in vitro and ex vivo (Wagner et al). 2003;73:272-4 (Letter)
- Prostatic neoplasms**
- Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer (Wong et al). 2003;73:304-11
- Protease inhibitors**
- Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors (Washington et al). 2003;73:406-16
- Publishing**
- Clinical Pharmacology & Therapeutics—an update (Stein). 2003;73:1-3 (Commentary)
- Concern about similarity of manuscripts (Verweij). 2003;73:274 (Letter)
- Pulmonary artery**
- Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (Barst et al). 2003;73:372-82

Q

QT interval; *see* Electrocardiography

Quality control

Drug therapy in the elderly: improving quality and access (Simon and Gurwitz). 2003;73:387-93 (Commentary)

Quinine

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (Christensen et al). 2003;73:517-28

R

Race factors

Medical practice, race, and drug use (Kalow). 2003;73:132-4 (Letter)
Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking (Kang et al). 2003;73:31-40

Receptors, adrenergic, beta

A common β_1 -adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β -blockade (Sofowora et al). 2003;73:366-71

Regression analysis

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis (Lee et al). 2003;73:348-65

Research

Use of healthy children as volunteers in drug studies: the ethical debate (Koren et al). 2003;73:147-52 (Commentary)

Retigabine

Effects of age and sex on the disposition of retigabine (Hermann et al). 2003;73:61-70

Rifabutin

Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin (Hamzeh et al). 2003;73:159-69

RNA, messenger

Coordinated intrahepatic and extrahepatic regulation of cytochrome P450D6 in healthy subjects and in patients after liver transplantation (Carcillo et al). 2003;73:456-67

Rosuvastatin

Effect of itraconazole on the pharmacokinetics of rosuvastatin (Cooper et al). 2003;73:322-9

S

Safety

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (Barst et al). 2003;73:372-82

St John's wort; *see* *Hypericum perforatum*

Seizures

Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures (Miller et al). 2003;73:491-505

Selectin

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Sex

Effects of age and sex on the disposition of retigabine (Hermann et al). 2003;73:61-70
Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking (Kang et al). 2003;73:31-40

Simvastatin

Response to "The efficacy of simvastatin is not influenced by CYP2D6 polymorphism" by Geisel et al (Mulder et al). 2003;73:475 (Letter)

Smoking

Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking (Kang et al). 2003;73:31-40

Somatotropin

Population pharmacodynamic analysis of octreotide in acromegalic patients (Comets et al). 2003;73:95-106

Subcutaneous infusions; *see* Infusions, subcutaneousSustained-release preparations; *see* Delayed-action preparations

T

Telithromycin

Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects (Démolis et al). 2003;73:242-52

Teriparatide

Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin (Benson and Voelker). 2003;73:87-94

Theophylline

Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma (Obase et al). 2003;73:468-74

Thioguanine

Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia (Derieux et al). 2003;73:506-16

Tobramycin

Routine early therapeutic drug monitoring is necessary during the first week of life (Stolk and Guillaume) (Letter); (de Hoog et al) (Reply). 2003;73:131-2

Treatment outcome

Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval (Peck et al). 2003;73:481-90 (Commentary)

Troglitazone

A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus (Watanabe et al). 2003;73:435-55

Tumor necrosis factor

Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor α or interleukin 1β release in vitro and ex vivo (Wagner et al). 2003;73:272-4 (Letter)Type two diabetes mellitus; *see* Diabetes mellitus, non-insulin-dependent

U

United States Food and Drug Administration

Drug labeling should be kept current (Rajpal and Reidenberg). 2003;73:4-6 (Commentary)

Uridine diphosphate

A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine (Sawyer et al). 2003;73:566-74

V

Vascular diseases

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease (Klinkhardt et al). 2003;73:232-41

Vasodilation

Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans (de Hoon et al). 2003;73:312-21

Verapamil

Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking (Kang et al). 2003;73:31-40

W

Warfarin

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients (Takahashi et al). 2003;73:253-63

White Americans

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients (Takahashi et al). 2003;73:253-63

Willow bark extract; *see* Plants, medicinal

Wine

Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice (Bailey et al). 2003;73:529-37

